The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway
Open accessAbstract
The neu (c-erbB-2) proto-oncogene encodes a tyrosine kinase receptor that is overexpressed in 20 to 30% of human breast tumors. Herein, cyclin D1 protein levels were increased in mammary tumors induced by overexpression of wild-type Neu or activating mutants of Neu in transgenic mice and in MCF7 cells overexpressing transforming Neu. Analyses of 12 Neu mutants in MCF7 cells indicated important roles for specific C-terminal autophosphorylation sites and the extracellular domain in cyclin D1 promoter activation. Induction of cyclin D1 by NeuT involved Ras, Rac, Rho, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38, but not phosphatidylinositol 3-kinase. NeuT induction of the cyclin D1 promoter required the E2F and Sp1 DNA binding sites and was inhibited by dominant negative E2F-1 or DP-1. Neu-induced transformation was inhibited by a cyclin D1 antisense or dominant negative E2F-1 construct in Rat-1 cells. Growth of NeuT-transformed mammary adenocarcinoma cells in nude mice was blocked by the cyclin D1 antisense construct. These results demonstrate that E2F-1 mediates a Neu-signaling cascade to cyclin D1 and identify cyclin D1 as a critical downstream target of neu-induced transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862 · cited 3×
“Cyclin D1 overexpression leads to the induction of pRB phosphorylation and the release of free E2F-1 (74), which is capable of inducing promoter activity through either Sp1 or E2F sites (30).”
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Self-citationRho GTPases and signaling networks
Van Aelst, L., & D’Souza-Schorey, C. (1997) · Genes & Development · doi:10.1101/gad.11.18.2295 · Cited by 2,358
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
High gradient magnetic cell separation with MACS
Miltenyi, S., Müller, W., Weichel, W., & Radbruch, A. (1990) · Cytometry · doi:10.1002/cyto.990110203 · Cited by 1,681
Minden, A., Lin, A., Claret, F.-X., Abo, A., & Karin, M. (1995) · Cell · doi:10.1016/s0092-8674(05)80019-4 · Cited by 1,478
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Self-citation
Cited by
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer
Black, A. R., Black, J. D., & Azizkhan‐Clifford, J. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1111 · Cited by 1,049
Minireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 966
Self-citationSpecific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
Harari, D., & Yarden, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203973 · Cited by 633
Self-citationThe ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
Citri, A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00101-5 · Cited by 595
Montalto, F. I., & De Amicis, F. (2020) · Cells · doi:10.3390/cells9122648 · Cited by 496
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Role of Curcumin in Cancer Therapy
Shishodia, S., Chaturvedi, M. M., & Aggarwal, B. B. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2007.04.001 · Cited by 413
Ronchini, C., & Capobianco, A. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5925-5934.2001 · Cited by 412
Fu, M., Wang, C., Reutens, A. T., Wang, J., Angeletti, R. H., Siconolfi-Baez, L., Ogryzko, V., Avantaggiati, M.-L., & Pestell, R. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000660200 · Cited by 409
Self-citationNovel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation
Yang, J., Chatterjee-Kishore, M., Staugaitis, S. M., Nguyen, H., Schlessinger, K., Levy, D. E., & Stark, G. R. (2005) · Cancer Research · doi:10.1158/0008-5472.939.65.3 · Cited by 405
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020450x · Cited by 396
NF-κB and cell-cycle regulation: the cyclin connection
JOYCE, D., ALBANESE, C., STEER, J., FU, M., BOUZAHZAH, B., & PESTELL, R. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00018-6 · Cited by 393
Self-citationSignal transduction and oncogenesis by ErbB/HER receptors
Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389
Self-citationReceptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., Lisanti, M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100800200 · Cited by 366
Self-citationA cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation
Yu, Z., Wang, C., Wang, M., Li, Z., Casimiro, M. C., Liu, M., Wu, K., Whittle, J., Ju, X., Hyslop, T., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200801079 · Cited by 363
Self-citationBouras, T., Fu, M., Sauve, A. A., Wang, F., Quong, A. A., Perkins, N. D., Hay, R. T., Gu, W., & Pestell, R. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408748200 · Cited by 355
Self-citationMukhopadhyay, A., Banerjee, S., Stafford, L. J., Xia, C., Liu, M., & Aggarwal, B. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206048 · Cited by 353
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
Julien, S. G., Dubé, N., Read, M., Penney, J., Paquet, M., Han, Y., Kennedy, B. P., Muller, W. J., & Tremblay, M. L. (2007) · Nature Genetics · doi:10.1038/ng1963 · Cited by 316
Self-citationSinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203947 · Cited by 290
Molecular targets for breast cancer therapy and prevention
Bange, J., Zwick, E., & Ullrich, A. (2001) · Nature Medicine · doi:10.1038/87872 · Cited by 288
Gene expression phenotypic models that predict the activity of oncogenic pathways
Huang, E., Ishida, S., Pittman, J., Dressman, H., Bild, A., Kloos, M., D'Amico, M., Pestell, R. G., West, M., & Nevins, J. R. (2003) · Nature Genetics · doi:10.1038/ng1167 · Cited by 263
Self-citationShimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells
Ryo, A., Liou, Y.-C., Wulf, G., Nakamura, M., Lee, S. W., & Lu, K. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5281-5295.2002 · Cited by 253
Altered Rho GTPase Signaling Pathways in Breast Cancer Cells
Burbelo, P., Wellstein, A., & Pestell, R. G. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000018422.02237.f9 · Cited by 82
Self-citationBowe, D. B., Kenney, N. J., Adereth, Y., & Maroulakou, I. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205025 · Cited by 61
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78818-0_12 · Cited by 59
Metadata
- Authors
- Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., Siegel, P. M., Hung, M.-C., Yarden, Y., Horowitz, J. M., Muller, W. J., & Pestell, R. G.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2000-01-15
- Volume
- 20
- Issue
- 2
- Pages
- 672-683
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2147746178
- Cited by
- 347
- References
- 79
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.